GlaxoSmithKline plc (LSE/NYSE: GSK) today announces a series of agreements with Aspen (JSE: APN) aligned with GSK’s strategy of simplification through focusing on core therapeutic areas.
GSK will divest its anaesthesia portfolio to Aspen for £180 million plus milestones of up to £100 million. In addition to this divestment, GSK and Aspen have entered into parallel agreements to terminate their collaboration in Sub-Saharan Africa and for Aspen to exercise its option to acquire GSK’s remaining thrombosis business in certain retained markets.